Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)

Woo Yeon Hwang1,2, Suk-Joon Chang3, Hee Seung Kim2, Nam Kyeong Kim1, Tae Hun Kim4, Yeorae Kim1, Tae Wook Kong3, Eun Ji Lee2, Soo Jin Park2, Seung Hyuk Shim5, Joo-Hyuk Son5, Dong Hoon Suh1,2* and Eun Jung Yang5

Abstract

Background: This study aims to evaluate the incidence of and identify risk factors for gastrointestinal (GI) and genitourinary (GU) fistula or perforation formation with or without bevacizumab in patients with recurrent cervical cancer who underwent pelvic radiation therapy (RT).

Methods: Medical records of patients with recurrent cervical cancer who previously underwent pelvic RT between 2007 and 2020 were retrospectively reviewed. Clinicopathological factors were compared between groups that are stratified according to: 1) fistula/perforation (+) versus (−); and 2) bevacizumab plus conventional chemotherapy (BC) versus chemotherapy alone (C). Univariate and multivariate regression analyses were performed to identify risk factors for fistula/perforation. Overall survival (OS) was compared between the different groups.

Results: Of 219 participants, fistula/perforation of any grade occurred in 36 patients (16.4%); 27 fistulas and 9 perforations. Bevacizumab was more frequently used in Bevacizumab was more frequently used (+) group than fistula/
Background
A significant number of patients with cervical cancer present with metastatic disease or experience recurrence after primary treatment [1]. Patients diagnosed with early stage cervical cancer may be cured using radical surgery, pelvic radiation therapy (RT), or both, while those with recurrent or persistent cervical cancer after RT have limited treatment options [2–4]. Platinum-based chemotherapy has been the mainstay of treatment for patients with recurrent disease who are not candidates for surgery or RT [5]. However, the mortality rate in patients with recurrent cervical cancer remains high. Therefore, there is a persistent need for safer and more effective therapies to prolong survival.

Angiogenesis, through a complex process involving vascular growth factors, plays a crucial role in the growth, progression, and metastasis of cervical cancer [6, 7]. Clinical evidence has been accumulating over the last decade regarding the efficacy of targeting vascular endothelial growth factor (VEGF) in cervical cancer. Bevacizumab, a recombinant humanized VEGF-neutralizing monoclonal antibody, was approved by the United States Food and Drug Administration for women with persistent, recurrent, or metastatic cervical cancer in August 2014 based on the Gynecologic Oncology Group (GOG) 240 study results [8]. GOG 240, a phase III randomized trial, showed a significant overall survival (OS) benefit conferred by the incorporation of bevacizumab in patients with recurrent, persistent, or metastatic cervical cancer [9]. While GOG 240 has resulted in a shift of standard treatment, adverse reactions such as gastrointestinal (GI) and genitourinary (GU) fistulas occurred at a higher frequency in patients treated with bevacizumab compared to patients treated with chemotherapy alone (C), and all patients who developed a fistula had a history of prior pelvic RT.

Following the GOG 240 study, the use of bevacizumab has increased for persistent, recurrent, or metastatic cervical cancer in Korea. However, there is a paucity of data regarding the fistulas or perforations involving the bowel and bladder, especially in patients with previously irradiated recurrent cervical cancer. In addition, although randomized controlled trials show significant results in terms of efficacy and safety, they do not always represent the real-world setting [10]. The purpose of this study is to evaluate the incidence rate and identify the risk factors for GI and GU fistula/perforation in patients receiving bevacizumab plus conventional chemotherapy (BC) for recurrent cervical cancer after pelvic RT in the Korean population. This study could provide evidence to guide counseling on the safety of the incorporation of bevacizumab in the treatment regimens of patients with recurrent cervical cancer who have previously undergone pelvic RT.

Methods
Study population
This multicenter retrospective study was conducted in accordance with the principles of the Declaration of Helsinki at five university hospitals in Korea. After approval from the institutional review boards, the medical records of patients diagnosed with recurrent cervical cancer, who had previously undergone pelvic RT between 2007 and 2020, were retrospectively reviewed. The requirement for written informed consent for the data collection was waived.

Eligible patients had been treated with external beam pelvis radiotherapy (EBRT) or concurrent chemoradiotherapy (CCRT). For RT, 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) was performed. Patients were treated with chemotherapy either with bevacizumab for at least 1 cycle or without bevacizumab for at least 3 cycles at recurrence. Patients treated with BC as primary treatment, those treated with BC before RT, those who have received prior pelvic RT for the treatment of other malignancies, those with concomitant malignancy or a history of other malignancies being present within the past five years, and those with a lack of clinical information or loss to follow-up during treatment were excluded. Women
who received chemotherapy immediately after RT were also excluded.

Data collection
Medical records were collected, including clinicopathological data such as age, history of diabetes mellitus or hypertension, year of diagnosis, histological type, and International Federation of Gynecology and Obstetrics (FIGO) stage. We restaged the patients according to the 2018 FIGO staging system. The details of primary treatment and RT, including RT modality, application of IMRT, cumulative dose of RT, and line of RT, were collected. In addition, the total number of recurrences; whether bevacizumab was administered with chemotherapy; and adverse events, including GI and GU fistula/perforation that occurred in patients, were sorted according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Statistical analysis
The analysis was conducted based on the occurrence of fistula/perforation and whether bevacizumab was administered, divided into fistula/perforation (+) and fistula/perforation (-) groups, and BC and C groups, respectively. Student’s t-test and Mann–Whitney U test were performed to compare continuous variables. Pearson’s chi-squared test or Fisher’s exact test was used to compare categorical variables. Univariate logistic regression analysis was performed to identify the risk factors for GI/GU fistula and perforation. Some of the risk factors in the univariate analysis were included in the multivariate logistic regression. In terms of survival outcomes, OS was calculated from the date of disease diagnosis to the date of the last follow-up or death due to any cause. The Kaplan–Meier survival curve with a log-rank test was used to compare survival outcomes. All analyses were performed using SPSS statistical software (version 21.0; SPSS Inc., Chicago, IL, USA). Statistical significance was set at P<0.05.

Results
A total of 219 patients were included in the analysis, consisting of 36 (16.4%) in the fistula/perforation (+) group and 183 (83.6%) in the fistula/perforation (-) group. The baseline patient characteristics are presented in Table 1. No differences in patient age, history of diabetes mellitus and hypertension, year of diagnosis, histologic type, 2018 FIGO stage, primary treatment, RT modality, application of IMRT, cumulative dose of RT, when patients received RT, and total number of recurrences were observed between the two groups. However, more patients in fistula/perforation (+) group had received BC than fistula/perforation (-) group (83.3% vs. 62.3%; P=0.015).

Table 1  Clinicopathologic characteristics of the fistula/perforation (+) and (-) groups

| Characteristics                  | All (n=219) | F/P (+)* (n=36) | F/P (-) (n=183) | P value |
|---------------------------------|------------|----------------|----------------|--------|
| Age, years                      | 51.0 ± 12.6| 47.8 ± 12.0    | 51.6 ± 12.6    | 0.119  |
| DM                              | 16 (7.3)   | 2 (5.6)        | 14 (7.7)       | > 0.999|
| HTN                             | 36 (16.4)  | 3 (8.3)        | 33 (18.0)      | 0.151  |
| Diagnosis, year                 |            |                |                | 0.258  |
| 2007–2013                       | 66 (30.1)  | 8 (22.2)       | 58 (31.7)      |        |
| 2014–2020                       | 153 (69.9) | 28 (77.8)      | 125 (68.3)     |        |
| Histology                       |            |                |                | 0.899  |
| SCC                             | 144 (65.8) | 24 (66.7)      | 120 (65.6)     |        |
| Non-SCC                         | 75 (34.2)  | 12 (33.3)      | 63 (34.4)      |        |
| FIGO stage                      |            |                |                | 0.831  |
| I                               | 61 (27.9)  | 11 (30.6)      | 50 (27.3)      |        |
| II                              | 46 (21.0)  | 7 (19.4)       | 39 (21.3)      |        |
| III                             | 89 (40.6)  | 14 (38.9)      | 75 (41.0)      |        |
| IV                              | 23 (10.5)  | 4 (11.1)       | 19 (10.4)      |        |
| Primary treatment               |            |                |                | 0.312  |
| OP                              | 14 (6.4)   | 3 (8.3)        | 11 (6.0)       |        |
| OP + RT                         | 95 (43.4)  | 12 (33.3)      | 83 (45.4)      |        |
| RT                              | 85 (38.8)  | 19 (52.8)      | 66 (36.1)      |        |
| CTx                             | 1 (0.5)    | 0 (0.0)        | 1 (0.5)        |        |
| Others                          | 24 (11.0)  | 2 (5.6)        | 22 (12.0)      |        |
| RT modality                     |            |                |                | 0.330  |
| EBRT alone                      | 23 (10.5)  | 2 (5.6)        | 21 (11.5)      |        |
| EBRT + ICR                      | 3 (1.4)    | 0 (0.0)        | 3 (1.6)        |        |
| CCRT                            | 118 (53.9) | 24 (66.7)      | 94 (51.4)      |        |
| CCRT + ICR                      | 75 (34.2)  | 10 (27.8)      | 65 (35.5)      |        |
| IMRT                            | 85 (38.8)  | 17 (47.2)      | 68 (37.2)      | 0.257  |
| RT dose                         |            |                |                |        |
| EBRT, Gy                        | 54.3 ± 13.7| 50.9 ± 8.8     | 51.1 ± 6.3     | 0.763  |
| ICR, Gy                         | 23.4 ± 12.1| 26.9 ± 20.9    | 23.0 ± 10.5    | 0.582  |
| RT                              | 188 (85.8) | 31 (86.1)      | 157 (85.8)     | 0.960  |
| Primary                         | 188 (85.8) | 31 (86.1)      | 157 (85.8)     |        |
| After 1st recur                 | 31 (14.2)  | 5 (13.9)       | 26 (14.2)      |        |
| Total no of recur               |            |                |                | 0.470  |
| ≥ 1                             | 51 (23.3)  | 11 (30.6)      | 40 (21.9)      |        |
| ≥ 3                             | 75 (34.2)  | 6 (16.7)       | 69 (37.7)      |        |

Values are presented as mean ± standard deviation or n (%) unless otherwise indicated.
F/P Fistula/Perforation, DM Diabetes Mellitus, HTN Hypertension, SCC Squamous Cell Carcinoma, FIGO International Federation of Gynecology and Obstetrics, OP Operation, RT Radiation Therapy, CTx Chemotherapy, EBRT External Beam Radiation Therapy, ICR Intracavitary Radiotherapy, CCRT Concurrent Chemoradiotherapy, IMRT Intensity-modulated Radiation Therapy
* Fistula/perforation (+) includes gastrointestinal / genitourinary fistula and gastrointestinal perforation.
We performed a subgroup analysis of the patients who received BC. The characteristics of the fistula/perforation (+) group (n = 30) and fistula/perforation (-) group (n = 114) of patients treated with bevacizumab are presented in Table 2. Among the variables, two were significantly different between the two groups. The fistula/perforation (+) group had fewer patients with a history of hypertension (6.7% vs. 22.8%; P = 0.029) and received fewer cycles of bevacizumab (5.5 ± 3.9 vs 6.7 ± 3.6; P = 0.028) than the fistula/perforation (+) group.

The complications of GI and GU fistula/perforation in the C and BC groups reported in this study are shown in Table 3. The overall cumulative incidence rates of fistula/perforation were 8.0% (6/75) and 20.8% (30/144) in the C group and BC group, respectively (hazards ratio [HR], 3.026; 95% confidence interval [CI], 1.199–7.640; P = 0.019). Although all complications of fistula/perforation in C group were severe ones with grade 3 or 4, the proportion of severe complications was still higher in BC group than C group (19.4% vs. 8.0%; P = 0.029).

The multivariate analysis in Table 4 revealed that administration of bevacizumab appeared to be the only independent risk factor for occurrence of fistula/perforation (HR, 3.273; 95% CI, 1.177–9.096; P = 0.023).

In addition, we compared the C and BC groups. Of 219 patients, 75 (34.2%) received C, and 144 (65.8%) received BC (Supplementary Table S1). Compared with group C, group BC had a significantly higher proportion of patients

---

**Table 2** Comparison of characteristics between fistula/perforation (+) and (-) groups in patients who received bevacizumab (n = 144)

| Characteristics          | F/P (+) (n = 30) | F/P (-) (n = 114) | P value |
|--------------------------|-----------------|------------------|---------|
| Age, years (mean ± SD)   | 48.1 ± 12.5     | 53.2 ± 13.3      | 0.084   |
| DM                       | 2 (6.7)         | 10 (8.8)         | >0.999  |
| HTN                      | 2 (6.7)         | 26 (22.8)        | 0.047   |
| Diagnosis, year          | 2007–2013       | 2014–2020        | 0.780   |
| Histology                |                 |                  | 0.729   |
| SCC                      | 21 (70.0)       | 76 (66.7)        |         |
| Non-SCC                  | 9 (30.0)        | 38 (33.3)        |         |
| FIGO stage               |                 |                  | 0.915   |
| I                        | 10 (33.3)       | 31 (27.2)        |         |
| II                       | 5 (16.7)        | 23 (20.2)        |         |
| III                      | 12 (40.0)       | 49 (43.0)        |         |
| IV                       | 3 (10.0)        | 11 (9.6)         |         |
| Primary treatment        |                 |                  | 0.987   |
| OP                       | 2 (6.7)         | 9 (7.9)          |         |
| OP followed by adjuvant RT | 12 (40.0)   | 43 (37.7)        |         |
| RT                       | 15 (50.0)       | 59 (51.8)        |         |
| Others                   | 1 (3.3)         | 3 (2.6)          |         |
| RT modality              |                 |                  | 0.123   |
| EBRT alone               | 1 (3.3)         | 8 (7.0)          |         |
| EBRT + ICR               | 0 (0.0)         | 0 (0.0)          |         |
| CCRT                     | 21 (70.0)       | 56 (49.1)        |         |
| CCRT + ICR               | 8 (26.7)        | 50 (43.9)        |         |
| IMRT                     | 15 (50.0)       | 57 (50.0)        | >0.999  |
| RT dose                  |                 |                  |         |
| EBRT, Gy                 | 52.9 ± 11.7     | 53.4 ± 12.5      | 0.690   |
| ICR, Gy                  | 23.5 ± 8.2      | 23.0 ± 6.4       | 0.400   |
| RT                       |                 |                  | 0.755   |
| Primary                  | 26 (86.7)       | 101 (88.6)       |         |
| After 1st recur          | 4 (13.3)        | 13 (11.4)        |         |
| Total no of recur        |                 |                  | 0.466   |
| 1                        | 13 (43.3)       | 46 (40.4)        |         |
| 2                        | 8 (26.7)        | 43 (37.7)        |         |
| ≥ 3                      | 9 (30.0)        | 25 (21.9)        |         |
| BEV administered at       |                 |                  | 0.371   |
| 1st recurrence           | 24 (80.0)       | 100 (87.7)       |         |
| ≥ 2nd recurrence         | 6 (20.0)        | 14 (12.3)        |         |
| BEV administered cycle    | 5.5 ± 3.9       | 6.7 ± 3.6        | 0.028   |
| Interval between RT and BEV administration, month | 16.3 ± 23.2 | 18.0 ± 17.7 | 0.212 |

Values are presented as mean ± standard deviation or n (%) unless otherwise indicated.

F/P Fistula/Perforation, DM Diabetes Mellitus, HTN Hypertension, SCC Squamous Cell Carcinoma, FIGO International Federation of Gynaecology and Obstetrics, OP Operation, RT Radiation Therapy, EBRT External Beam Radiation Therapy, ICR Intracavitary Radiotherapy, IMRT Intensity-modulated Radiation Therapy, BEV Bevacizumab.

a Fistula/perforation (+) includes gastrointestinal / genitourinary fistula and gastrointestinal perforation.

**Table 3** Occurrence of fistula and perforation according to bevacizumab administration

|                          | C (n = 75) | BC (n = 144) | RR (95% CI) | P value |
|--------------------------|-----------|-------------|-------------|---------|
| GI fistula               |           |             |             |         |
| Grade 2                  | 0 (0.5)   | 1 (0.5)     | NA          | >0.999  |
| Grade 3                  | 2 (0.9)   | 5 (3.2)     | 1.313 (0.249–6.934) | 0.748  |
| Grade 4                  | 0 (0.5)   | 3 (1.4)     | NA          | 0.999   |
| GU fistula               |           |             |             |         |
| Grade 2                  | 0 (0.5)   | 1 (0.5)     | NA          | >0.999  |
| Grade 3                  | 1 (0.5)   | 5 (3.2)     | 2.662 (0.305–23.208) | 0.376  |
| Grade 4                  | 0 (0.5)   | 1 (0.5)     | NA          | >0.999  |
| GI fistula & GU fistula  |           |             |             |         |
| Grade 3                  | 0 (0.5)   | 7 (3.2)     | NA          | 0.999   |
| Grade 4                  | 0 (0.5)   | 1 (0.5)     | NA          | >0.999  |
| GI perforation           |           |             |             |         |
| Grade 3                  | 2 (0.9)   | 4 (1.8)     | 1.043 (0.187–5.829) | 0.962  |
| Grade 4                  | 1 (0.5)   | 2 (0.9)     | 1.042 (0.093–11.684) | 0.973  |
| Total                    |           | 6 (8.0)     | 30 (20.8)   | 3.026 (1.199–7.640) | 0.019  |

Values are presented as n (%) unless otherwise indicated.

C Chemotherapy alone, BC Bevacizumab plus Conventional chemotherapy, RR Risk Ratio, CI Confidence Interval, NA Not Available, GI Gastrointestinal, GU Genitourinary.
who were diagnosed in later period between 2014 and 2020 (41.3% vs. 84.7%; \( P < 0.001 \)). Regarding RT modality, patients who received RT only for primary treatment (14.7% vs. 51.4%; \( P < 0.001 \)), CCRT with ICR (22.7% vs. 40.3%; \( P < 0.001 \)) and IMRT (17.3% vs. 50.0%; \( P < 0.001 \)) were more frequent in group BC than group C. Patients who were treated by EBRT alone, however, were more frequent in group C than group BC (18.7% vs. 6.3%; \( P < 0.001 \)). Multivariate analyses of the risk factors for administration of bevacizumab showed that year of diagnosis (HR, 9.704; 95% CI, 4.171–22.579; \( P < 0.001 \)) and use of IMRT (HR, 2.192; 95% CI, 1.009–4.762; \( P = 0.047 \)) were independent risk factors for administration of bevacizumab (Supplementary Table S2). Since the GOG 240 study was published in 2014, we performed another sub-group analysis of risk factors for fistula/perforation only in the patients after 2014 (Supplementary Table S3). The results showed that there were no significant risk factors related to fistula/perforation.

During a median length of follow-up of 33.7 months (range, 1.2–185.6 months), 55 patients (25.1%) expired, and no significant OS difference was observed between the fistula/perforation (+) group vs. fistula/perforation (-) group (HR, 1.782; median, 129.5 months [95% CI, 114.1–144.9] vs. 84.2 months [95% CI, 59.3–109.0]; \( P = 0.065 \)) or between C vs. BC group (HR, 1.026; median, 115.7 months [95% CI, 96.0–135.4] vs. 119.8 months [95% CI, 97.3–142.3]; \( P = 0.928 \) (Fig. 1).

**Discussion**

Platinum-based chemotherapy with bevacizumab is one of the most promising treatment options for recurrent or persistent cervical cancer [5, 8]. However, our study results suggest that the incorporation of bevacizumab in the chemotherapy regimen for the treatment of recurrent cervical cancer in patients with a previous history
of pelvic RT incurs considerable risk for GI and/or GU fistula or perforation complications. We failed to identify other independent risk factors for developing GI/GU fistula or perforation in this study population. GI and/or GU fistula or perforation may influence the survival outcomes, as well as quality of life.

Differences were found between our study and the GOG 240 study. Our results showed a notably higher rate of fistula/perforation in both groups compared to the GOG 240 study (20.8% vs. 8.0%). The GOG 240 study reported an incidence of severe fistula/perforation of 5.9% (13/220) in BC group and 0.5% (1/220) in C group [9]. All patients with fistulas had previous received RT, even if it was not indicated which modality of RT was applied. There was another study that reported an increase in fistula formation up to 22% in the real-world population [11]. In terms of OS, in our study, BC group did not show a significant improvement compared to C group, while the GOG 240 study showed a significant improvement in OS. However, the GOG 240 data on two distinct chemotherapy doublets with bevacizumab showed different results. When compared with the cisplatin plus paclitaxel chemotherapy, patients who received additional bevacizumab showed a significant OS improvement (HR 0.73 [95% CI 0.54–0.99]; \( P = 0.04 \)), while topotecan plus paclitaxel alone and topotecan plus paclitaxel plus bevacizumab did not show a significant difference in OS [9]. Therefore, the lack of difference in OS in our study may be due to the different components of chemotherapy regimens. In Korea, weekly cisplatin and cisplatin plus paclitaxel are the most commonly-used regimens for CCRT and systemic therapy, respectively. Carboplatin plus paclitaxel, paclitaxel only and cisplatin plus topotecan are also used for some patients [12].

Our results have several interesting perspectives. IMRT delivers higher radiation doses focused on the tumor while minimizing the dose delivered to normal structures [13]. Contrary to our expectations, our study showed that IMRT does not reduce GI or GU complications neither in the overall sample of patients nor in the subgroup treated with bevacizumab. A previous meta-analysis showed results distinct from those of our study. The study compared the clinical outcomes and toxicities of IMRT with 3D-CRT or conventional two-dimensional radiotherapy (2D-RT) for definitive treatment of cervical cancer showing that although IMRT was not superior to 3D-CRT or 2D-RT in OS but it reduced acute GI and GU toxicities, as well as chronic GU toxicity [14]. However, IMRT is still associated with significant rectal and cystic toxicity. Wu et al. [15] reported higher GI toxicities in IMRT group than conventional RT group, which was consistent with our study results. Wu et al. described that there were unavoidable hot spots with uncertain high dose to rectum and bladder which may increase complications by reviewing the IMRT planning [15]. Our findings may also have been affected by high doses delivered to rectum and bladder when IMRT was administered.

In the BC group, more patients were diagnosed after 2014, and more patients were treated with IMRT (Supplement Table S1). This is thought to be related to the time when IMRT and bevacizumab were introduced to the treatment regimens for patients with gynecological
cancer in Korea. The implementation of IMRT is related to the policies of the national health insurance in Korea. IMRT was first introduced in 2001 in Korea, and since July 2015, insurance coverage of this procedure was expanded to include most cancers [16]. In addition, the United States Food and Drug Administration approved bevacizumab in combination with first-line chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer in 2014 based on GOG 240 [17]. Therefore, the year of diagnosis of cervical cancer and application of IMRT may have been confounded by the health insurance, the year of publication and approval.

Our study is unique compared to previous studies that addressed bevacizumab complications due the uniqueness of our study population. We evaluated fistula/perforation caused by bevacizumab in patients with previously irradiated recurrent cervical cancer. In addition, being a multicenter study with data collected from five large university hospitals in Korea makes our study results more likely to be generalized to the Korean population. However, our study had several limitations. First, there may be potential bias due to the retrospective nature of our study. Second, the insurance system and unique healthcare environment in Korea may have influenced our results. Third, we did not collect every single data on the treatment regimen for all treatment steps for CCRT or systemic chemotherapy. The difference in regimens may be a risk factor for complications or may influence OS, as mentioned above. Finally, data on the performance status of patients could not be obtained, as we collected the data from medical records.

In conclusion, our study results suggest that the incorporation of bevacizumab in chemotherapy regimen for the treatment of recurrent cervical cancer in patients with a previous history of pelvic RT incurs considerable risk of GI and GU fistula or perforation, which might compromise the survival outcome, as well as quality of life. Careful weighing of the risks and benefits of incorporating bevacizumab is needed in the treatment of patients with previously irradiated recurrent cervical cancer, considering that effective prevention of fistula/perforation complications is difficult because of the lack of other identifiable risk factors.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09695-x.

**Additional file 1: Supplement Table S1.** Comparison of characteristics according to the use of bevacizumab. Supplement Table S2. Univariate and multivariate analyses of the risk factors for GI/GU fistula and perforation associated with bevacizumab use. Supplement Table S3. Univariate and multivariate analyses of the risk factors for GI/GU fistula and perforation associated with bevacizumab use after 2014.

**Acknowledgements**
We thank all gynecologic oncologists who were attending physicians of the patients enrolled in this study but not included as co-authors for kindly supporting our study.

**Authors’ contributions**
Conceptualization and study design: WYH, DHS; Data acquisition: WYH, NKK, YK; Analysis and interpretation of data: WYH, DHS, SC, HSK, NKK, THK, YK, TWK, EJ, SJP, SHS, JS, EJY; Methodology: WYH, DHS; Writing-original draft: WYH; Writing-review & editing: WYH, DHS; Supervision: DHS, SC, HSK, THK, TWK, SHS. The author(s) read and approved the final manuscript.

**Funding**
Not applicable.

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**
This multicenter retrospective study was conducted in accordance with the principles of the Declaration of Helsinki after approval from the institutional review boards at five university hospitals (Seoul National University Bundang Hospital, No. B-2104–608-101; Ajou University School of Medicine, No. AJIRB-MED-MDB-21–178; Seoul National University College of Medicine, No. J-2104–206-1215; Seoul Metropolitan Government Seoul National University Boramae Medical Center, No. 30–2021-69; Konkuk University School of Medicine, No KUMC 2021–03-094) in Korea. The requirement for written informed consent for the data collection was waived from the IRBs of five university hospitals: Seoul National University Bundang Hospital IRB, Ajou Medical Center IRB; Seoul National University College of Medicine, Seoul National University Hospital IRB; Seoul Metropolitan Government Seoul National University Boramae Medical Center IRB; Konkuk University Medical Center IRB.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interest.

**Author details**

1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Suwon, Republic of Korea. 3Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea. 4Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 5Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.

Received: 22 March 2022 Accepted: 23 May 2022
Published online: 02 June 2022

**Abbreviations**
GI: Gastrointestinal; GU: Genitourinary; BC: Bevacizumab plus conventional chemotherapy; RT: Radiation therapy; F/P: Fistula/Perforation; C: Chemotherapy alone; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; VEGF: Vascular endothelial growth factor; GOG: Gynecologic Oncology Group; EBRT: External beam pelvic radiotherapy; CCRT: Concurrent chemoradiotherapy; 3D-CRT: 3-Dimensional conformal radiation therapy; IMRT: Intensity-modulated radiation therapy; DM: Diabetes mellitus; FIGO: International Federation of Gynecology and Obstetrics; CTCAE: Common Terminology Criteria for Adverse Events.
References

1. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015;11:909–22.

2. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:i72–83.

3. Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Virchows Arch. 2018;472:919–36.

4. Cervical Cancer (Version 1.2021) https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.

5. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4640–55.

6. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, et al. Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther. 2014;7:2237–48.

7. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014;6:280–92.

8. FDA approves avastin for aggressive and metastatic cervical cancer. 2014;36:9.

9. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240). Lancet. 2017;390:1654–63.

10. Čerina D, Matković V, Katić K, BelacLovasić I, Separović R, Canjko I, et al. Real-world efficacy and safety of bevacizumab in the first-line treatment of metastatic cervical cancer: a cohort study in the total population of croatian patients. J Oncol. 2021;2021:2815623.

11. Godoy-Ortiz A, Plata Y, Alcaide J, Galeote A, Pajares B, Saez E, et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients. Clin Transl Oncol. 2018;20:922–7.

12. Lim MC, Lee M, Shim SH, Nam EJ, Lee JY, Kim HJ, et al. Practice guidelines for management of cervical cancer in Korea: a Korean Society of gynecologic oncology consensus statement. J Gynecol Oncol. 2017;28:e22.

13. Hong TS, Ritter MA, Tomé WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer. 2005;92:1819–24.

14. Lin Y, Chen K, Liu Z, Zhao L, Tao Y, Ouyang Y, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol. 2018;13:177.

15. Wu H-H, Chen JC-H, Tai H-C, Chang K-H, Chia P-S. Intensity-modulated radiotherapy with concurrent chemotheraphy for elder cervical cancers: a comparison of clinical outcomes with conventional radiotherapy. Int J Gerontol. 2016;10:159–63.

16. Huh SJ, Park W, Choi DH. Recent trends in intensity-modulated radiation therapy use in Korea. Radiat Oncol J. 2019;37:249–53.

17. Minion LE, Tewari KS. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther. 2017;17:191–8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions